Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience
| Autor: | Azra Hasic, Amina Kurtovic Kozaric, Semir Beslija, Sabira Kurtovic, Lejla Mehinovic, Erna Islamagic |
|---|---|
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 35:e18549-e18549 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2017.35.15_suppl.e18549 |
| Popis: | e18549 Background: In this study we examined the long-term real life clinical outcomes of patients receiving front- line nilotinib and patients who switched from branded or generic imatinib to nilotinib (second-line therapy) in Bosnia and Herzegovina. Methods: Patients in CML-CP (n = 70) who started their TKI treatment in period from June 2005 to August 2016 were included in this multicentre retrospective cohort study. Patients were categorized as: Group 1 (n = 31) contained patients receiving front-line nilotinib (300 mg twice daily) and Group 2 (n = 39) consisted of patients who started with front-line imatinib (Glivec or generic imatinib) and then were switched to nilotinib (400 mg or 600 mg twice daily). Nilotinib became available as front or second-line therapy in March 2011. Standard patients' variables were collected and disease progression was established as loss of CCyR and MMR. Survival probabilities were estimated with the Kaplan-Meier method and compared using the log-rank test. Results: Seventy patients (median age was 54.5 years; 61% was males) were enrolled in this study. The median follow-up was 39 months (range 3-51 months). Median wait period for therapy was 12 months (range 1-62) from diagnosis. In both studied groups, overall survival was 87% at 39 months. According to ITT principle, achievement of CCyR and MMR at 24 months on nilotinib therapy was higher in Group 1 compared to Group 2 (81% vs 67% and 74% vs 49%, respectively). Rate of death was similar in both studied groups (4/31 vs 5/39). In Group 2, five patients who had suboptimal response on front-line imatinib discontinued therapy (median period of 19.5 months) were switched when nilotinib became available. Interestingly, none of these patients died. Conclusions: Our results suggest that at 3 years, there was no difference in the overall suvival between studied groups. However, achievement of CCyR and MMR at 24 months was higher in patients on front-line nilotinib therapy. Patients who waited for therapy had optimal response regardless the wait period on nilotinib therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|